The directive was issued by the Indian Pharmacopoeia Commission (IPC) in a letter signed by its secretary-cum-scientific director, V Kalaiselvan, citing concerns about underreporting of adverse events, including cases linked to domestically made equipment. Reporting is to be done on the government’s MvPI system, which the health ministry launched to monitor, record and analyze adverse events associated with medical devices. The article notes the instruction comes in the context of an India recall of a Johnson & Johnson hip replacement device after global reports of metal poisoning and high failure rates, and follows earlier guidance from India’s drug regulator for manufacturers to set up systems for timely adverse-event identification and reporting.